{"product_id":"tpst-ansoff-analysis","title":"(TPST) Tempest Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Tempest Therapeutics, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to show how the company can expand its oncology and immuno-oncology pipeline and enter new markets. The page contains a real preview\/sample of the analysis so you can see style and substance before buying; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTPST-1495 Phase 1 solid-tumor enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics can deepen penetration in oncology by advancing TPST-1495 in its first-in-human Phase 1 solid-tumor study, a direct way to build share of mind with trial sites already running cancer programs. More enrolled patients should expand the human data set on dual EP2\/EP4 inhibition, the core biology behind this asset. A larger enrollment base also helps Tempest sharpen dose, safety, and early efficacy signals faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTPST-1120 Phase 1 solid-tumor enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTPST-1120’s continued Phase 1 enrollment in solid tumors is a clear market penetration move, because Tempest Therapeutics, Inc. is keeping the same oncology program active in the same patient pool. The company has one lead small-molecule candidate in clinical testing, so steady enrollment helps preserve pipeline visibility while it stays clinical-stage. It also reinforces its niche in small-molecule oncology development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-guided patient selection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiomarker-guided patient selection fits Tempest Therapeutics, Inc.’s market penetration play because its pathway-based drugs can be tested in the same solid-tumor market, but in patients most likely to respond. Solid tumors account for about 90% of adult cancers, so narrowing enrollment can improve response rates, speed readouts, and reduce wasted trial spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCombination-cohort expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics can deepen market penetration by adding combination cohorts for TPST-1495 and TPST-1120 in solid tumors, where combo regimens are the trial norm. This lifts clinical relevance without changing the core oncology market, and it fits a capital-light expansion model for a company that reported about $15.2 million in cash and cash equivalents at year-end 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroaden use in the same tumor classes\u003c\/li\u003e\n\u003cli\u003eTest more partners, same assets\u003c\/li\u003e\n\u003cli\u003eRaise trial relevance, not market scope\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConference and publication cadence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics had no approved products in 2025, so steady Phase 1 readouts are a key market-penetration tool. In oncology, visibility at ASCO and ESMO can help drive investigator interest, site activation, and partner outreach; those meetings reach tens of thousands of specialists each year. For a small clinical-stage Company Name, cadence is commercial signal, not just science.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore updates can support trial recruitment.\u003c\/li\u003e\n\u003cli\u003eConference presence can lift partner attention.\u003c\/li\u003e\n\u003cli\u003eRegular data drops can widen competitive visibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest Expands Solid-Tumor Testing With $15.2M Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. is using market penetration by deepening TPST-1495 and TPST-1120 testing in the same solid-tumor pool, with no approved products in 2025. Solid tumors make up about 90% of adult cancers, so each added cohort raises visibility without changing the market. The company had about $15.2 million in cash and cash equivalents at 2024 year-end.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and cash equivalents\u003c\/td\u003e\n\u003ctd\u003e$15.2 million at 2024 year-end\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget market\u003c\/td\u003e\n\u003ctd\u003eSolid tumors, about 90% of adult cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Tempest Therapeutics, Inc.’s growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Tempest Therapeutics Ansoff Matrix to quickly pinpoint growth options and reduce strategy-planning friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, and peer-reviewed sources to validate Tempest Therapeutics’ Ansoff Matrix growth paths for fast, defensible decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdditional solid-tumor indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics can expand its lead assets into additional solid-tumor settings, which fits its tumor-agnostic biology and avoids the cost of a new molecule. Solid tumors account for about 90% of adult cancers, so each new indication can lift the total addressable market fast. This kind of market development can extend one mechanism across multiple cancers, raising clinical optionality without a full R\u0026amp;D reset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader oncology-center recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader oncology-center recruitment is a market development move for Tempest Therapeutics, Inc. It keeps the same two lead assets, TPST-1495 and TPST-1120, but opens trial access to more patient pools and more clinicians. That wider site network can speed enrollment, with one program set and more centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew patient subgroups by pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest can practice market development by using the same prostaglandin- and PPARalpha-driven assets to reach new, biomarker-defined patient groups. That widens the addressable population without changing the drug, which fits precision oncology. In 2025, Tempest still had just 2 core pathway themes to build on, so pathway-aligned recruitment can expand trial reach fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeographic trial reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can widen trial reach by adding sites beyond South San Francisco, which helps recruit more patients and investigators without changing the drug. In oncology, faster enrollment matters because only about 3% to 5% of adults with cancer join clinical trials, so more geographies can reduce delay risk.\u003c\/p\u003e\n\u003cp\u003eThis is a low-change market development move: same assets, broader access, and better site diversity for readouts. It fits a clinical-stage company with no approved products and lets Tempest scale development before any commercial launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand into new trial geographies\u003c\/li\u003e\n\u003cli\u003eIncrease patient and investigator access\u003c\/li\u003e\n\u003cli\u003eKeep the investigational drugs unchanged\u003c\/li\u003e\n\u003cli\u003eSpeed enrollment and de-risk timelines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic-oncology network expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExpanding into more academic oncology sites gives Tempest Therapeutics, Inc. access to new trial patients for the same assets, especially TPST-1495 and TPST-1120. NCI-designated cancer centers, which number 71 in the U.S., are key for biomarker testing and early efficacy reads in solid tumors, so this move can widen clinical reach without changing the drug program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore sites, same assets.\u003c\/li\u003e\n\u003cli\u003eBetter biomarker and response data.\u003c\/li\u003e\n\u003cli\u003eBroader TPST-1495 and TPST-1120 exposure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest’s Growth Path: Bigger Solid-Tumor Markets, Faster Trial Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can grow by moving TPST-1495 and TPST-1120 into more solid-tumor settings and more oncology sites. This market development keeps the same assets, but opens larger patient pools and faster enrollment. With only 2 core pathway themes in 2025, Tempest can scale reach without new chemistry.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew indications\u003c\/td\u003e\n\u003ctd\u003eSolid tumors are about 90% of adult cancers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial access\u003c\/td\u003e\n\u003ctd\u003eOnly 3% to 5% join cancer trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite reach\u003c\/td\u003e\n\u003ctd\u003e71 U.S. NCI centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTempest Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report, so buy now to unlock the complete, editable Ansoff Matrix for Tempest Therapeutics with strategic recommendations and market actions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTREX-1 program advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTREX-1 program advancement is a clear product development move for Tempest Therapeutics, because it turns an explored biology into a defined drug asset. It would expand the oncology pipeline from 2 candidates, TPST-1495 and TPST-1120, to 3 programs, adding a new asset class rather than a new market. That widens Tempest Therapeutics, Inc.'s shot on goal without leaving oncology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-generation EP2 and EP4 inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can use TPST-1495 learnings to design next-generation EP2 and EP4 inhibitors with better potency, selectivity, and developability. That is product development because it upgrades the same receptor-inhibition franchise, not a new market. With no product revenue and continued R\u0026amp;D spending in the latest fiscal filings, a stronger successor around the same pathway could be the clearest way to add value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-generation PPARalpha blockade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can use TPST-1120 as the lead for a 2nd PPARalpha compound if more tuning is needed, keeping the program in the same target class while improving PK and safety.\u003c\/p\u003e\n\u003cp\u003eThat fits early oncology R\u0026amp;D, where back-up molecules are a standard step before expensive 2\/3-stage trials; Phase 1\/2 work often narrows risk fast.\u003c\/p\u003e\n\u003cp\u003eWith one lead asset already in hand, follow-ons can protect the platform and preserve value even if the first molecule needs optimization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTranslational biomarker package\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can pair pathway-driven small molecules with a translational biomarker package to raise product value by matching the right patients to the right drug and tracking early response signals in Phase 1 solid-tumor studies. This matters because proof-of-mechanism in Phase 1 often comes from small cohorts and can shape go\/no-go calls fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eImproves patient selection\u003c\/li\u003e\n\u003cli\u003eTracks early response\u003c\/li\u003e\n\u003cli\u003eSupports Phase 1 proof-of-mechanism\u003c\/li\u003e\n\u003cli\u003eAdds value to each program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCombination regimen refinement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRefining TPST-1495 and TPST-1120 combinations is product development, because Tempest Therapeutics, Inc. is changing how these assets are used in trials, not adding a new drug. In oncology, combo regimens often beat monotherapy, and Tempest’s Phase 2 work has centered on shaping a clinical profile that can support later-line use.\u003c\/p\u003e\n\u003cp\u003eThat matters because Tempest reported a $0 market cap with a small cash base and no approved products, so better regimen design can lift asset value faster than a single-agent path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCombo-first positioning can improve efficacy signals.\u003c\/li\u003e\n\u003cli\u003eTrial design shapes TPST-1495 and TPST-1120 value.\u003c\/li\u003e\n\u003cli\u003eBetter regimens can support future partnering.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest’s Value Case: Better Follow-Ons, Broader Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. uses product development to extend TPST-1495 and TPST-1120 into better-fit follow-ons, not new markets. Its latest filings still show no product revenue and a small cash base, so upgrading potency, selectivity, PK, and biomarker fit is the fastest path to value. A 3rd oncology asset widens the pipeline and keeps risk inside one franchise.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eLatest\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore oncology programs\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue lever\u003c\/td\u003e\n\u003ctd\u003eFollow-on assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-program pipeline beyond 2 clinical assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. still has 2 named clinical candidates, so adding a 3rd program would widen its oncology pipeline and cut reliance on one mechanism or asset. That matters in a capital-light model, where each new program can spread clinical risk across more shots on goal. It also shifts the company from a narrow 2-asset story toward a broader oncology portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnate-immunity mechanism expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc.’s interest in TREX1 signals diversification into innate-immune regulation inside oncology, not a move into a new industry. That is a different path from EP2 and EP4 inhibition or PPARalpha blockade, so it broadens the future pipeline. It can widen the product set while still staying cancer-focused.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew small-molecule target classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. reported no product revenue in FY2025, so adding new small-molecule target classes would broaden its science base beyond the two current mechanisms. That is a realistic discovery-led biotech move: one validated target can seed more than one future program. It also lowers pipeline concentration risk and can support longer-term value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdditional solid-tumor biology programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can diversify by adding more distinct solid-tumor biology programs, so its pipeline is not tied to one pathway or one asset. That keeps the cancer focus intact while widening the shot at clinical success and reducing concentration risk, which matters most for a clinical-stage biotech with limited revenue and high R\u0026amp;D burn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore tumor pathways, broader portfolio\u003c\/li\u003e\n\u003cli\u003eSame oncology focus, less asset risk\u003c\/li\u003e\n\u003cli\u003eBetter odds of pipeline survival\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture immuno-oncology assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. can use its tumor-biology and immune-signaling know-how to add more immuno-oncology assets, which is a new product line in a new oncology niche. This is the clearest diversification path in its Ansoff Matrix because it extends the same research base into adjacent therapies. \u003c\/p\u003e\n\u003cp\u003eThe global oncology drug market was about $220 billion in 2024, so even one added immuno-oncology program can target a large addressable pool. The main risk is still high R\u0026amp;D burn, but the upside is a broader pipeline and less dependence on a single mechanism. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew products, new niche\u003c\/li\u003e\n\u003cli\u003eUses existing biology expertise\u003c\/li\u003e\n\u003cli\u003eBest-fit diversification route\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTempest’s 3rd Oncology Asset Could Cut Risk and Broaden Its Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTempest Therapeutics, Inc. uses diversification to add more oncology programs without leaving cancer. With FY2025 product revenue of $0 and only 2 named clinical candidates, a 3rd asset would spread clinical risk, widen its mechanism mix, and reduce dependence on any one program.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025\/2026 view\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue FY2025\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNamed clinical candidates\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiversification effect\u003c\/td\u003e\n\u003ctd\u003eLower asset risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235128353033,"sku":"tpst-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tpst-ansoff-matrix.webp?v=1785733942","url":"https:\/\/dcfanalyst.com\/products\/tpst-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}